ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2021
Genetic differences between benign phyllodes tumors and fibroadenomas revealed through targeted next generation sequencing.
Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Malignant phyllodes tumor of the breast: a systematic review.Pathologica · 2022Pooled it
- Molecular pathology of phyllodes tumours of the breast-much more than MED12.Histopathology · 2026Review
- From Proteomics to Pathology: S100A8's Impact on Breast Phyllodes Tumors Grading.Annals of surgical oncology · 2026Article
- Integrative multi-omics reveals common and distinct pathogenic mechanisms and preoperative diagnostic signatures in breast fibroepithelial lesions.Breast cancer research : BCR · 2025Article
- Recent Advances in Malignant Phyllodes Tumors of the Breast.Journal of breast cancer · 2025Review
- From Fibroadenoma to Phyllodes Tumor: Case Analysis of Borderline and Giant Breast Tumors with Literature Review.Acta medica Lituanic · 2025Article
- Salivary Metabolites in Breast Cancer and Fibroadenomas: Focus on Menopausal Status and BMI.Metabolites · 2024Article
- Epithelial to mesenchymal transition (EMT) in metaplastic breast cancer and phyllodes breast tumors.Medical oncology (Northwood, London, England) · 2023Review
- Periductal Stromal Tumor of the Breast with aInternational journal of surgical pathology · 2023Article
- Gene Expression Profiling of Fibroepithelial Lesions of the Breast.International journal of molecular sciences · 2023Article
- Giant Phyllodes Tumor in an 82-Year-Old Female Initially Diagnosed a Fibroadenoma: A Case Report.Cureus · 2022Article
- Article
- Surgical management and prognosis of phyllodes tumors of the breast.Gland surgery · 2022Article
- Artificial intelligence modelling in differentiating core biopsies of fibroadenoma from phyllodes tumor.Laboratory investigation; a journal of technical methods and pathology · 2022Article
- A comprehensive next generation sequencing tissue assay for Asian-prevalent cancers-Analytical validation and performance evaluation with clinical samples.Frontiers in molecular biosciences · 2022Article
- Fibroepithelial tumours of the breast-a review.Virchows Archiv : an international journal of pathology · 2022Review
- Large borderline phyllodes breast tumor related to histopathology, diagnosis, and treatment management - case report.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast fibroepithelial lesions are biphasic tumors which comprise the common benign fibroadenomas (FAs) and the rarer phyllodes tumors (PTs). This study analyzed 262 (42%) conventional FAs, 45 (7%) cellular FAs, and 321 (51%) benign PTs contributed by the International Fibroepithelial Consortium, using a previously curated 16 gene panel. Benign PTs were found to possess a higher number of mutations, and higher rates of cancer driver gene alterations than both groups of FAs, in particular MED12, TERT promoter, RARA, FLNA, SETD2, RB1, and EGFR. Cases with MED12 mutations were also more likely to have TERT promoter, RARA, SETD2, and EGFR. There were no significant differences detected between conventional FAs and cellular FAs, except for PIK3CA and MAP3K1. TERT promoter alterations were most optimal in discriminating between FAs and benign PTs. Our study affirms the role of sequencing and key mutations that may assist in refining diagnoses of these lesions.
Indexed as
Identifiers
33727697What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.